ArticleIBRO neuroscience reports2025
Assessment of differences in clinical consequences between rituximab and interferon recipients in multiple sclerosis patients after recovery from COVID-19.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) patients using disease-modifying treatments (DMTs) are at serious danger from the Coronavirus Disease 2019 (COVID-19) pandemic, which is brought on by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This could make infections more severe. This study postulated that because of the immunosuppressive effects of Rituximab, MS patients treated with this medication would have worse clinical outcomes after recovering from COVID-19 than those treated with Interferon. Method: This cross-sectional study at Imam Khomeini Hospital, Urmia, Iran, included 34 MS patients with confirmed COVID-19 (2019-2022), treated with Interferon (n = 12) or Rituximab (n = 22). Demographic data, MS phenotype, Expanded Disability Status Scale (EDSS), COVID-19 severity, hospitalization duration, mortality, and reinfection rates were analyzed using SPSS version 27. Statistical comparisons used independent t-tests and Chi-square/Fisher's exact tests (p < 0.05). Result: Patients had a mean age of 44.74 ± 8.85 years (range: 18-60). Rituximab-treated patients had significantly longer hospitalizations (6-10 days: 10 vs. 5 patients, 11-20 days: 5 vs. 0, p = 0.032, 95 % CI: 1.2-3.5), higher mortality (3 vs. 0, p = 0.041, odds ratio: 2.8, 95 % CI: 1.1-7.2), greater MS severity (EDSS≥2: 18 vs. 2, p = 0.028, 95 % CI: 1.3-4.1), and higher reinfection rates (8 vs. 0, p = 0.037, 95 % CI: 1.2-5.0) compared to Interferon-treated patients. Conclusion: Compared to interferon, rituximab was linked to worse clinical outcomes in MS patients after COVID-19 recovery, indicating that its use during pandemics should be used with caution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.